Incyte has received marketing authorisation from the European Commission for Opzelura (ruxolitinib) cream 15mg/g to treat non-segmental vitiligo with facial involvement in adults and in adolescents aged 12 years and above.

Opzelura is the first and only approved treatment across the European Union (EU) aimed at achieving repigmentation in the targeted patients.

Non-segmental vitiligo is a chronic autoimmune disease characterised by skin depigmentation and a minimised quality of life.

The latest approval comes after the European Medicines Agency’s committee for medicinal products for human use (CHMP) provided a positive opinion earlier in 2023.

It applies across the 27 EU member states, as well as Iceland, Norway and Liechtenstein.

The approval is based on results from two pivotal Phase lll trials assessing the efficacy and safety of Opzelura against vehicle (non-medicated cream) in more than 600 people aged 12 and above, suffering from non-segmental vitiligo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Incyte CEO Hervé Hoppenot said: “The approval of Opzelura by the European Commission represents a significant advancement for people living with non-segmental vitiligo with facial involvement who, until now, had no approved medical treatment to address repigmentation.

“This approval wouldn’t have been possible without the support of the vitiligo patient and medical community, and the efforts of our research and development teams.

“We will now work across individual countries in Europe to bring this much-awaited therapy to eligible patients seeking to treat their vitiligo.”